drugset / Trial / NCT04975217

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

NCT04975217

Phase 0 Suspended 10 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This early phase I trial examines the safety and effects of fecal microbial transplants in treating patients with pancreatic cancer. scheduled for surgery to remove tumors. Fecal microbial transplant contains the normal microbes found in fecal (stool) material. Giving fecal microbial transplant may help control the disease.

Timeline

Start
2021-12-14
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ornidazole Other / unclassified Oral